NCT01085058View on ClinicalTrials.gov

"Predictive Value of the Cytocapacity Test Patients With Lymphoproliferative Diseases and High-dose Therapy"

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

169

Participants

Timeline

Start Date

May 31, 2003

Primary Completion Date

December 31, 2004

Study Completion Date

December 31, 2004

Conditions

Hodgkin's DiseaseNon-Hodgkin LymphomasMultiple Myelomas

Interventions

DRUG

lenograstim

Sponsors

Collaborators (1)

Chugai Pharma GmbH

All Listed Sponsors

collaborator

Ludwig-Maximilians - University of Munich

OTHER

collaborator

Chugai Pharma GmbH

UNKNOWN

lead

WiSP Wissenschaftlicher Service Pharma GmbH

OTHER

NCT01085058 - "Predictive Value of the Cytocapacity Test Patients With Lymphoproliferative Diseases and High-dose Therapy" | Biotech Hunter | Biotech Hunter